Top Header Mobile

Updates

Contact

 Session Chair Profile

img-Vanessa_Soros

Ph.D., VP, Research and Early Development, Graphite Bio

Vanessa Soros

Biography
 Dr. Vanessa Soros is VP of Research and Early Development of Graphite Bio, a gene editing and cell therapy company, leading discovery research and development efforts. Prior to Graphite Bio, Dr. Soros was Sr. Director of Antibody Development and Engineering at Tizona Therapeutics, where her work led to several first-in-class antibody therapeutics to novel immune-oncology targets. Prior to Tizona, Vanessa was a lead scientist in the development of discovery platforms and screening systems for novel biologics at both Catalyst Biosciences and Sea Lane Biotechnologies. Vanessa obtained her Ph.D. from the University of Toronto in Molecular Biology and Medical Genetics and pursued her postdoctoral studies at the Gladstone Institute of Virology and Immunology, at the University of California, San Francisco.


 Session Abstract – PMWC 2022 Silicon Valley

img-Cutting Edge Technologies for Gene Engineering and Cell Therapy (PANEL)

Cutting Edge Technologies for Gene Engineering and Cell Therapy (PANEL)
Track 1 - June 30 9.15 A.M.-10.15 P.M.


Panel

 Session Abstract – PMWC 2022 Silicon Valley

img-Cell and Gene Therapies Track

Cell and Gene Therapies Track
Track 1 - June 30 9.15 A.M.-10.15 P.M.


Track Chair:
Vanessa Soros, Graphite Bio

Sessions:

  • Gene & Cell Therapies Overview
    - Janice Chen, Mammoth
  • Cutting Edge Technologies for Gene Engineering and Cell Therapy (PANEL)
    Session Chair: Vanessa Soros, Graphite Bio
    - Mark McKee, Intellia Tx
    - Amy Simon, Beam Therapeutics
    - Eric Ostertag, Poseida Therapuetics
  • Translating CGT to the Clinic (PANEL)
    Session Chair: Nicole K. Paulk, UCSF
    - Matthew Porteus, Stanford
    - Peter Francis, 4D Molecular Therapeutics
    - Erandi De Silva, Forge Biologics
    - Patrice Hugo, Q2 Solutions
    - Susanne Fors, Ultragenyx
  • PMWC Showcase
    - Yuri Fesko, Labcorp
    - Yan Zhang, Mission Bio
    - Anil Narasimha, Mekonos Inc.
    - Emily Anderson, Horizon, a PerkinElmer Company
    - Jesse Salk, Twinstrand
    - William Shrader, AcureX Therapeutics
  • Emerging Gene Therapies for Epidermolysis Bullosa
    - Peter Marinkovich, Stanford
  • Past, Present and Future of CRISPR Where will CRISPR Take Us and How is the Technology Evolving to Realize its Full Potential (PANEL)
    Session Chair: Janice Chen, Mammoth
    - Kiana Aran, Cardea Bio
    - Mark McKee, Intellia Tx
    - Josh Lehrer, Graphite Bio